News
Feed
Events
Feed
News
+ Events
Feed

Vivoryon Therapeutics N.V.

  • ISIN NL00150002Q7
  • Land Deutschland

Aktuelle News

28 November 2022

13:30 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer’s Disease Conference (CTAD)

23 November 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares (news with additional features)

22 November 2022

07:20 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress (news with additional features)

14 November 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022

30 September 2022

08:47 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress (news with additional features)

08:45 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million (news with additional features)

26 September 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022

31 Juli 2022

18:05 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 (news with additional features)

18:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (news with additional features)

23 Juni 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD (news with additional features)

22 Juni 2022

19:13 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022 (news with additional features)

15 Juni 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress (news with additional features)

8 Juni 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022

11 Mai 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 (news with additional features)

28 April 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress (news with additional features)

21 April 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

20 April 2022

12:01 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

1 April 2022

08:47 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million (news with additional features)

31 März 2022

17:45 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement (news with additional features)

7 März 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

28 Februar 2022

01:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer’s Disease (news with additional features)

4 Januar 2022

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences

22 Dezember 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer’s Disease (news with additional features)

4 November 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress (news with additional features)

1 November 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021

18 Oktober 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease (news with additional features)

21 September 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress (news with additional features)

14 September 2021

07:00 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress

9 September 2021

16:41 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

29 Juni 2021

01:11 Corporate EN

Vivoryon Therapeutics N.V.

Corporate
EN

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance

Anstehende Events

Keine Events gefunden